$131.22▲ 2.38 (1.85%)
Real-time prices · US MarketsQ·Score
Buy
8.1 / 10
High-quality business with 41% return on equity and 29% profit margins.
Quality
9.3
Health
7.6
Growth
7.9
Valuation
7.5
Sentiment
7.6
Analyst Target
$158.36
▲ +20.7% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
19.4×
price-to-earnings
Forward P/E
13.6×
next 12 months est.
Market Cap
$162.9B
market capitalization
Div Yield
2.55%
dividend yield
Profit Margin
28.9%
net profit margin
Gross Margin
78.8%
revenue minus COGS
ROE
40.7%
return on equity
Beta
0.40
vs S&P 500
Price / Book
—
P/B ratio
52-Week Range
$95 — $157
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
Is GILD a good stock to buy right now?
Based on our Q·Score of 8.1/10, Gilead Sciences, Inc. is rated "Buy". High-quality business with 41% return on equity and 29% profit margins. This analysis is based on fundamentals, analyst consensus, and valuation data, and should not be considered financial advice.
What is the analyst price target for GILD?
The consensus price target for GILD is $158.36, based on the recommendations of 28 Wall Street analysts. This implies 20.7% upside from the current price of $131.22.
Is GILD overvalued or undervalued?
Gilead Sciences, Inc. (GILD) appears reasonably valued or undervalued relative to analyst targets and sector peers. It trades at a 13.6× forward P/E ratio. Analysts see 21% upside to their $158.36 consensus target.
When does Gilead Sciences, Inc. report its next earnings?
Gilead Sciences, Inc. is scheduled to report earnings in 7 days, on May 7, 2026.
What is Gilead Sciences, Inc.'s profit margin?
Gilead Sciences, Inc. has a net profit margin of 28.9%, which is considered high and reflects strong pricing power. Its gross margin stands at 78.8%, indicating a high-margin business model.
What is GILD's dividend yield?
Gilead Sciences, Inc. currently offers a dividend yield of 2.55%, which provides a solid income stream for dividend-focused investors. Dividend yields can change based on price movements and company payout decisions.
Is Gilead Sciences, Inc.'s revenue growing?
Gilead Sciences, Inc. is reporting modest revenue growth of 4.7%. Earnings are also growing at 23.4%, indicating improving profitability.
How much debt does Gilead Sciences, Inc. have?
Gilead Sciences, Inc. has a debt-to-equity ratio of 1.13×, reflecting a moderately high debt load — watch cash flow coverage. Its current ratio is 1.55×, indicating comfortable short-term liquidity.